Jeffrey Lawrence Appointed Chairman of Joe & the Juice
Joe & the Juice (“the Company”), an urban juice bar and coffee concept selling freshly prepared juices, coffee, sandwiches and more, today announced that Jeffrey Lawrence, a member of the Company’s Board of Directors since April 2024, has been appointed as Chairman of the Board.
Thomas Nørøxe, Chief Executive Officer of Joe & the Juice, said, “Jeff’s elevation to Chairman of Joe & the Juice reflects how his active participation has made a material difference to the Company’s performance and strategy. Over the past year, Joe & the Juice has achieved continued impressive same store sales and revenue growth as we also opened our 400th unit globally. Unit economics remain incredibly strong and digital sales are now nearing 40%. Jeff’s experience will be vital as we continue to expand globally through both company-owned and franchise openings.”
Jeffrey Lawrence commented, “Joe & the Juice continues to represent one of the most exciting and dynamic restaurant brands, with true global consumer appeal. Over time, the Company has finetuned a winning formula to provide fresh, quality products, with a focus on hospitality and meeting the needs of today’s digitally-enabled consumer. I have been inspired by the ambition and potential of the team and look forward to working closely together to continue to build the Joe & the Juice brand globally.”
Mr. Lawrence holds more than 25 years of leadership experience in building digitally-enabled foodservice and consumer brands. He spent more than two decades at Domino’s Pizza (NYSE: DPZ), including five years as Executive Vice President and Chief Financial Officer, playing a critical role in the company’s successful IPO, its significant international expansion and best in class increases in store-level profitability. Mr. Lawrence was also an integral part of the global pizza chain’s transformation through the adoption and optimization of digital and data-led initiatives.
After his time at Domino’s, Mr. Lawrence served as CFO of FIGS, Inc. (NYSE: FIGS), a direct-to-consumer apparel brand, where he led the company’s 2021 IPO, and then as CFO at ShiftKey.
He currently serves as an independent board member and Chairman of the Audit Committee at Shake Shack (NYSE: SHAK) and an independent board member at Xponential Fitness (NYSE: XPOF), as well as a Senior Advisor to General Atlantic, a leading global growth investor.
Joe & the Juice currently operates in more than 400 locations across 19 countries spanning the UK and Europe, United States, Middle East and Asia. Capitalizing on strong customer demand, the Company’s enhanced digital distribution channels and strong franchising partnerships have enabled it to rapidly expand its regional presence in key markets.
About Joe & the Juice
Joe & the Juice is an urban juice bar and coffee concept operating in more than 400 locations across 19 countries. Founded in 2002, the company sells freshly prepared juices, coffee, sandwiches and more. Joe & the Juice’s differentiated concept creates a modern, urban, and hip ambiance for on-the-go customers focused on a healthy lifestyle. For more on our authentic and unique brand: www.joejuice.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424086704/en/
Contacts
Media Contacts
Joe & the Juice
Kasper Garnell
garnell@joejuice.com
+45 2019 5904
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom